Anal Dysplasia
11
2
3
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
18.2%
2 terminated out of 11 trials
60.0%
-26.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
PDT Plus Vitamin D3 for Anal Dysplasia
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Application of Oral Bacteriotherapy to Promote Anal HPV Clearance in HIV Positive Individuals
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Screening for HIV-Associated Anal Cancer
Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia